Aileron Therapeutics has entered a clinical trial collaboration with Pfizer to evaluate the combination of ALRN-6924 and palbociclib in MDM2-amplified cancers.
The Phase Ib trial is expected to start enrolling patients with solid tumours in the first quarter of next year.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Pfizer will support the trial by providing a supply of its drug palbociclib for testing with Aileron’s ALRN-6924.
The first-in-class, stabilised cell-permeating peptide ALRN-6924 mimics the p53 tumour suppressor protein to disrupt the interaction with endogenous inhibitors MDMX and MDM2.
Aileron Therapeutics president and CEO Manuel Aivado said: “We are excited about this combination trial with Pfizer’s palbociclib. The combination of ALRN-6924 and palbociclib demonstrated enhanced antitumor activity and meaningfully delayed tumour growth in animal models over single agents alone.
“We believe the combination of these two drugs represents a complementary attack on the proliferation of cancer cells that may benefit patients with a variety of different cancers.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataALRN-6924 will be capable of restoring p53-dependent tumour suppression for p53 wild-type tumours.
Also known as IBRANCE, Pfizer’s palbociclib is an oral inhibitor of cell cycle check-point regulators CDK4/6.
The MDM2 and CDK4 genes are located close to one another on chromosome 12, with CDK4 very frequently co-amplified in the MDM2-amplification-positive patients who will be enrolled in the trial.
This co-amplification further suggests a potential patient benefit from combining the MDM2/MDMX-inhibitor ALRN-6924 with the CDK4/6-inhibitor palbociclib.
The stabilised helical structure of Aileron’s peptides allows the design of cell-permeating therapeutic agents with large molecular surfaces for optimal target binding properties. This will result in new drugs such as ALRN-6924.
